Literature DB >> 11184735

AIDS. Boosting immunity to HIV--can the virus help?

B Autran1, G Carcelain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11184735     DOI： 10.1126/science.290.5493.946

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  7 in total

1.  Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.

Authors:  Marc Wirden; Constance Delaugerre; Anne Genevieve Marcelin; Nadine Ktorza; Hocine Ait Mohand; Stephanie Dominguez; Luminita Schneider; Jade Ghosn; Michele Pauchard; Dominique Costagliola; Christine Katlama; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  HIV Vaccine Strategies - an Update.

Authors:  A K Sahni; A Nagendra
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.

Authors:  Daria Trabattoni; Sergio Lo Caputo; Mara Biasin; Elena Seminari; Massimo Di Pietro; Giovanni Ravasi; Francesco Mazzotta; Renato Maserati; Mario Clerici
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

4.  Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapy.

Authors:  Christina C Chang; Andrew Lim; Saleha Omarjee; Stuart M Levitz; Bernadett I Gosnell; Tim Spelman; Julian H Elliott; William H Carr; Mohamed-Yunus S Moosa; Thumbi Ndung'u; Sharon R Lewin; Martyn A French
Journal:  J Infect Dis       Date:  2013-06-12       Impact factor: 5.226

5.  Nonlinear observer output-feedback MPC treatment scheduling for HIV.

Authors:  Ryan Zurakowski
Journal:  Biomed Eng Online       Date:  2011-05-27       Impact factor: 2.819

6.  Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.

Authors:  Omar Sued; Juan Ambrosioni; David Nicolás; Christian Manzardo; Fernando Agüero; Xavier Claramonte; Montserrat Plana; Montserrat Tuset; Tomás Pumarola; Teresa Gallart; José María Gatell; José María Miró
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

7.  Constant drug dose in human immuno-deficiency virus-infected patients to induce long-term non-progressor status: bifurcation and controllability approach.

Authors:  Wonhee Kim; Han Byul Chung; Chung Choo Chung
Journal:  IET Syst Biol       Date:  2013-06       Impact factor: 1.615
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.